Exosomal PD-L1 Level in plasma as a predictive marker for diagnosis and clinical correlation in non-small cell lung cancer

Chulalongkorn University Systems biology center0 个研究点目标入组 70 人开始时间: 2021年8月8日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1.Aged 18 years or older
•2.Body weight > 30 kg
•3.NSCLC patients with confirmed diagnosis by tissue biopsy
•4.Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens
•5.Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors
•(RECIST) version 1.1

•1.Pregnant and lactating women
•2.Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder or superior vena cava syndrome)
•3.Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to randomisation, unstable arrhythmias or unstable angina
•i.Patients with a known left ventricular ejection fraction (LVEF) < 40% will be excluded
•4.Severe infections within 4 weeks after receiving treatment including but not limited to hospitalisation for complications of infection, bacteraemia or severe pneumonia
•5.Known active or untreated central nervous system (CNS) metastases
•6.Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome

发起方

Chulalongkorn University Systems biology center